Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma

被引:7
|
作者
Shi, Zhong-Xing [1 ]
Li, Chang -Fu [2 ]
Zhao, Li-Feng [3 ]
Sun, Zhong-Qi [4 ]
Cui, Li -Ming [1 ]
Xin, Yan-Jie [4 ]
Wang, Dong-Qing [1 ]
Kang, Tan-Rong [1 ]
Jiang, Hui-Jie [4 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Intervent Radiol, Harbin 150086, Peoples R China
[2] Daqing Longnan Hosp, Dept Digest Med, Daqing 163453, Peoples R China
[3] Daqing Longnan Hosp, Dept Radiol, Daqing 163453, Peoples R China
[4] Harbin Med Univ, Affiliated Hosp 2, Dept Radiol, Harbin 150086, Peoples R China
关键词
Hepatocellular carcinoma; Transarterial chemoembolization; Radiomics; Treatment response; Prediction; PROGNOSIS;
D O I
10.1016/j.hbpd.2023.06.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: According to clinical practice guidelines, transarterial chemoembolization (TACE) is the standard treatment modality for patients with intermediate -stage hepatocellular carcinoma (HCC). Early prediction of treatment response can help patients choose a reasonable treatment plan. This study aimed to investigate the value of the radiomic-clinical model in predicting the efficacy of the first TACE treatment for HCC to prolong patient survival. Methods: A total of 164 patients with HCC who underwent the first TACE from January 2017 to September 2021 were analyzed. The tumor response was assessed by modified response evaluation criteria in solid tumors (mRECIST), and the response of the first TACE to each session and its correlation with overall survival were evaluated. The radiomic signatures associated with the treatment response were identified by the least absolute shrinkage and selection operator (LASSO), and four machine learning models were built with different types of regions of interest (ROIs) (tumor and corresponding tissues) and the model with the best performance was selected. The predictive performance was assessed with receiver operating characteristic (ROC) curves and calibration curves. Results: Of all the models, the random forest (RF) model with peritumor ( + 10 mm) radiomic signatures had the best performance [area under ROC curve (AUC) = 0.964 in the training cohort, AUC = 0.949 in the validation cohort]. The RF model was used to calculate the radiomic score (Rad-score), and the optimal cutoff value (0.34) was calculated according to the Youden's index. Patients were then divided into a high -risk group (Rad-score > 0.34) and a low -risk group (Rad-score <= 0.34), and a nomogram model was successfully established to predict treatment response. The predicted treatment response also allowed for significant discrimination of Kaplan -Meier curves. Multivariate Cox regression identified six independent prognostic factors for overall survival, including male [hazard ratio (HR) = 0.500, 95% confidence interval (CI): 0.260-0.962, P = 0.038], alpha-fetoprotein (HR = 1.003, 95% CI: 1.002-1.004, P < 0.001), alanine aminotransferase (HR = 1.003, 95% CI: 1.0 01-1.0 05, P = 0.025), performance status (HR = 2.400, 95% CI: 1.20 0-4.80 0, P = 0.013), the number of TACE sessions (HR = 0.870, 95% CI: 0.780-0.970, P = 0.012) and Rad-score (HR = 3.480, 95% CI: 1.416-8.552, P = 0.007). Conclusions: The radiomic signatures and clinical factors can be well -used to predict the response of HCC patients to the first TACE and may help identify the patients most likely to benefit from TACE. (c) 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:361 / 369
页数:9
相关论文
共 50 条
  • [41] TRANSARTERIAL CHEMOEMBOLIZATION IN THE INTERMEDIATE STAGE OF HEPATOCELLULAR CARCINOMA: SURVIVAL ANALYSIS
    Tajibaev, T. K.
    Medeubekov, U. Sh
    Chormanov, A. T.
    Sagatov, I. Y.
    Kaniev, Sh A.
    Issamatov, B. K.
    Baimakhanov, B. B.
    NEW ARMENIAN MEDICAL JOURNAL, 2019, 13 (02): : 111 - 114
  • [42] Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma
    Lei Chen
    Xuefeng Kan
    Tao Sun
    Yanqiao Ren
    Yanyan Cao
    Liangliang Yan
    Bin Liang
    Bin Xiong
    Chuansheng Zheng
    BMC Gastroenterology, 20
  • [43] Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Labgaa, Ismail
    Taffe, Patrick
    Martin, David
    Clerc, Daniel
    Schwartz, Myron
    Kokudo, Norihiro
    Denys, Alban
    Halkic, Nermin
    Demartines, Nicolas
    Melloul, Emmanuel
    LIVER CANCER, 2020, 9 (02) : 138 - 147
  • [44] Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma
    Chen, Lei
    Kan, Xuefeng
    Sun, Tao
    Ren, Yanqiao
    Cao, Yanyan
    Yan, Liangliang
    Liang, Bin
    Xiong, Bin
    Zheng, Chuansheng
    BMC GASTROENTEROLOGY, 2020, 20 (01)
  • [45] A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation
    Jia-yan Ni
    Zhu-ting Fang
    Hong-liang Sun
    Chao An
    Zhi-mei Huang
    Tian-qi Zhang
    Xiong-ying Jiang
    Yao-ting Chen
    Lin-feng Xu
    Jin-hua Huang
    European Radiology, 2020, 30 : 2377 - 2390
  • [46] Development of a Model to Predict Liver Decompensation prior to Transarterial Chemoembolization Refractoriness in Patients with Intermediate-Stage Hepatocellular Carcinoma
    Ferreira-Silva, Joel
    Costa-Moreira, Pedro
    Cardoso, Helder
    Liberal, Rodrigo
    Pereira, Pedro
    Macedo, Guilherme
    GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 2023, 30 (01) : 29 - 37
  • [47] Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization before designing clinical trials comparing transarterial chemoembolization and immune checkpoint inhibitor-based therapies
    Koroki, Keisuke
    Ogasawara, Sadahisa
    Ooka, Yoshihiko
    Kanzaki, Hiroaki
    Kanayama, Kengo
    Maruta, Susumu
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Saito, Tomoko
    Kondo, Takayuki
    Suzuki, Eiichiro
    Nakamoto, Shingo
    Tawada, Akinobu
    Chiba, Tetsuhiro
    Arai, Makoto
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Kato, Jun
    Kuboki, Satoshi
    Ohtsuka, Masayuki
    Kato, Naoya
    JOURNAL OF HEPATOLOGY, 2020, 73 : S903 - S903
  • [48] Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization
    Raoul, J. -L.
    Sangro, B.
    Forner, A.
    Mazzaferro, V.
    Piscaglia, F.
    Bolondi, L.
    Lencioni, R.
    CANCER TREATMENT REVIEWS, 2011, 37 (03) : 212 - 220
  • [49] OVERALL SURVIVAL IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA (HCC) PATIENTS AFTER FIRST TRANSARTERIAL CHEMOEMBOLIZATION (TACE): PROPOSAL OF A NEW SCORING SYSTEM
    Sacco, R.
    Ginanni, B.
    Mismas, V.
    Masi, G.
    De Simone, P.
    Romano, A.
    Bresci, G.
    Bartolozzi, C.
    Bargellini, I.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 : E44 - E44
  • [50] A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation
    Ni, Jia-yan
    Fang, Zhu-ting
    Sun, Hong-liang
    An, Chao
    Huang, Zhi-mei
    Zhang, Tian-qi
    Jiang, Xiong-ying
    Chen, Yao-ting
    Xu, Lin-feng
    Huang, Jin-hua
    EUROPEAN RADIOLOGY, 2020, 30 (04) : 2377 - 2390